Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-253 in Advanced Solid Tumors
NCT06209580Phase 2Recruiting
- Sponsor
- Multitude Therapeutics
- Start
- Jan 2024
- Primary completion
- Apr 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of AMT-253 in Malignant Melanoma (MM), solid tumor (advanced stage), sponsored by Multitude Therapeutics. Started Jan 2024; status: recruiting.
02
Drugs
AMT-253
03
Conditions
Malignant Melanoma (MM)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06209580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06209580.